Flamel Technologies S.A. (NASDAQ:AVDL) – Equities researchers at SunTrust Banks cut their Q3 2017 earnings per share (EPS) estimates for Flamel Technologies in a report issued on Tuesday. SunTrust Banks analyst J. Boris now forecasts that the company will post earnings of ($0.03) per share for the quarter, down from their prior forecast of ($0.02). SunTrust Banks also issued estimates for Flamel Technologies’ Q4 2017 earnings at ($0.12) EPS, FY2018 earnings at $0.33 EPS, FY2019 earnings at $0.50 EPS, FY2020 earnings at $1.05 EPS and FY2021 earnings at $1.98 EPS.
A number of other analysts have also recently commented on the stock. Roth Capital set a $15.00 target price on shares of Flamel Technologies and gave the company a “buy” rating in a report on Wednesday. Zacks Investment Research cut shares of Flamel Technologies from a “hold” rating to a “sell” rating in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $14.75.
Flamel Technologies (NASDAQ AVDL) opened at 8.62 on Friday. Flamel Technologies has a 12-month low of $8.14 and a 12-month high of $15.45. The firm has a market cap of $345.52 million, a P/E ratio of 9.10 and a beta of 1.37. The firm’s 50-day moving average is $10.09 and its 200 day moving average is $9.97.
Flamel Technologies (NASDAQ:AVDL) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.14. Flamel Technologies had a net margin of 21.13% and a return on equity of 29.86%. The firm had revenue of $46.30 million for the quarter, compared to the consensus estimate of $45.17 million. The business’s revenue was up 19.0% on a year-over-year basis.
In related news, Director Craig R. Stapleton purchased 31,013 shares of the stock in a transaction dated Monday, May 22nd. The stock was purchased at an average price of $9.85 per share, with a total value of $305,478.05. Following the transaction, the director now directly owns 507,678 shares in the company, valued at $5,000,628.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 261,000 shares of Flamel Technologies stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $10.68, for a total value of $2,787,480.00. The disclosure for this sale can be found here. 5.07% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the company. Sei Investments Co. raised its position in Flamel Technologies by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after buying an additional 2,900 shares in the last quarter. Trexquant Investment LP raised its position in Flamel Technologies by 30.7% in the second quarter. Trexquant Investment LP now owns 30,500 shares of the company’s stock valued at $336,000 after buying an additional 7,169 shares in the last quarter. Columbus Circle Investors raised its position in Flamel Technologies by 16.7% in the second quarter. Columbus Circle Investors now owns 51,137 shares of the company’s stock valued at $564,000 after buying an additional 7,315 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in Flamel Technologies by 27.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 42,090 shares of the company’s stock valued at $464,000 after buying an additional 9,175 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Flamel Technologies by 2,484.0% in the second quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after buying an additional 10,532 shares in the last quarter. 71.03% of the stock is owned by hedge funds and other institutional investors.
Flamel Technologies Company Profile
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Ratings for Flamel Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.